RxDoctor Payments Data

Shirley Griffey, NP

Psychiatric/Mental Health · Baton Rouge, LANPI 1184015919

Payments from drug & device makers

$1,106in general payments, 2019–2025

Across 87 payments — averaging $12.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$276
  • Johnson & Johnson$192
  • Sunovion Pharmaceuticals Inc.$117
  • Takeda Pharmaceuticals U.S.A., Inc.$112
  • Otsuka America Pharmaceutical, Inc.$94
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$93
  • plus $223 from 7 others

What the payments were for

  • Food & beverage$1,07898%
  • Education$272%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,106 in reported general payments places this provider in the 45th percentile of 615 psychiatric/mental health providers in Louisiana.

See all psychiatric/mental health providers in Louisiana

Medicare billing

Part B allowed, 2024
$45,645
Medicare patients
179
Services billed
532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate71$233,721
RexultiBrexpiprazole96$107,711
VraylarCariprazine Hcl23$40,778
LybalviOlanzapine/Samidorphan Malate12$21,965
TrintellixVortioxetine Hydrobromide41$21,410
VyvanseLisdexamfetamine Dimesylate27$10,071
Quetiapine Fumarate509$9,241
Trazodone Hcl605$8,995
Lurasidone Hcl64$5,130
Aripiprazole164$5,064
Ziprasidone Hcl56$4,507
Duloxetine Hcl225$4,075
Clonazepam470$3,889
Olanzapine208$3,788
Mirtazapine229$3,707

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$192$233,72171 claims
Otsuka America Pharmaceutical, Inc.Rexulti$94$107,71196 claims
AbbVieVraylar$276$40,77823 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$112$31,48268 claims
Teva Pharmaceuticals USA, Inc.Loxapine$26$1,22717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 615 psychiatric/mental health providers in Louisiana.

Other psychiatric/mental health in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →